Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03776968

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Metastatic Castration Resistant Prostate Cancer Clinical Trial

Official title:
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics in Healthy Chinese Adults

Clinical Trial Summary

This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults. The study primary objective is to evaluate the HC-1119 pharmacokinetic characteristics and the effect of food on its pharmacokinetics in healthy Chinese males, subsequent to a single oral administration of HC-1119 with different doses in healthy Chinese males.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03776968
Study type Interventional
Source Hinova Pharmaceuticals Inc.
Contact
Status Completed
Phase Phase 1
Start date October 24, 2017
Completion date July 3, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02495974 - European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Completed NCT03641560 - A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy Phase 4
Terminated NCT02441517 - A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment Phase 4
Active, not recruiting NCT03454750 - Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) Phase 2
Completed NCT02471469 - Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
Terminated NCT03177187 - Combination Study of AZD5069 and Enzalutamide. Phase 1/Phase 2
Terminated NCT03531827 - Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Phase 2
Completed NCT02566772 - Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer Phase 1
Completed NCT03829436 - TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers Phase 1
Terminated NCT05241613 - A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 1
Recruiting NCT05369000 - Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT02975934 - A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Phase 3
Active, not recruiting NCT04869488 - A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer Phase 2
Completed NCT00428220 - A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. N/A
Completed NCT04056754 - Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer Phase 3
Completed NCT03658447 - PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) Phase 1/Phase 2
Terminated NCT03042312 - Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy Phase 2
Completed NCT02991911 - A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer Phase 1
Completed NCT02655822 - Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Phase 1
Completed NCT02426333 - Optimizing Abiraterone Therapy